+ Watch MELA
on My Watchlist
A medical device company which focuses on designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma.
With the accuracy of the MELAFind device being statistically significant in comparison with dermatologists and with it's non-invasive nature it is sure to be a winning device.
MelaFind works to a standard, equal in every doctor's office, in the world. 5 million doctors, across the world, each look at a mole differently, and, they cannot look below the dermis. MelaFind looks below the dermis. This imaging device is a stable "platform" from which to make decisions, improving the lives of the people who suspect, or have, melanoma. Just like X-rays, MRI, CAT scans, etc., nothing is perfect. FDA must consider the help this device will provide. 120,000 new melanoma cases each year. FDA must approve in November 2010. If a member of the FDA Committee was afflicted with this disease, or suspected it, or have a loved one with suspicious moles, etc. THAT FDA MEMBER would want MelaFind to be approved. It's a tool that cannot hurt, it can only help. AND, SINCE THERE IS NO CURE FOR METASTIC MELANOMA, HOW CAN THIS DIAGNOSTIC TOOL NOT BE OFFERED TO DOCTORS, TO SAVE LIVES. My wife is a Melanoma victim,she had surgery to remove a melanoma Stage I mole. They removed a large section of muscle tissue. I want her doctor to chart her body with MelaFind. Regards, Joe
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions